# A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

> **NCT06723652** · PHASE3 · COMPLETED · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 55 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** SHR-1918
- **DRUG:** SHR-1918 placebo

## Key facts

- **NCT ID:** NCT06723652
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-13
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-11-18
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723652, "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06723652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*